Test Price
2,800 AED✅ Home Collection Available
POU4F3 Gene Deafness (Autosomal Dominant Type 15) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- ✓ Clinical Guidance: Telephonic Post-Test Genetic Counseling in result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The POU4F3 NGS test identifies pathogenic variants in the POU4F3 gene responsible for autosomal dominant non‑syndromic sensorineural hearing loss (DFNA15). Our DHA‑licensed test delivers 99.9% analytical sensitivity using next‑generation sequencing with Sanger confirmation, and results guide personalized audiological and genetic counseling.
| Feature | Our Test (DHA‑Licensed) | Closest Alternative |
|---|---|---|
| Precision | Full POU4F3 gene sequencing + deletion/duplication analysis (CNV detection) | Limited targeted mutation panel or exome sequencing with lower depth |
| Methodology | Next‑Generation Sequencing (NGS) with Sanger confirmation of all variants | Sanger sequencing only (no CNV analysis) or microarray with restricted coverage |
| Turnaround Time | 3–4 Weeks from sample receipt | 6–8 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I emphasize that a positive POU4F3 result provides a definitive genetic diagnosis, enabling early intervention and family planning. However, it must be interpreted in the context of complete audiological assessment and family history. I strongly advise against making any clinical decisions without professional genetic counseling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria
Individuals unable to provide informed consent (e.g., severe cognitive impairment without a legal guardian). This test is not intended for patients with acute ear infections requiring immediate medical management.
Emergency Red Flags
If you experience sudden hearing loss, severe vertigo, or acute tinnitus, seek urgent ENT evaluation. This genetic test is elective and not designed for emergency diagnosis.
Patient FAQ & Clinical Guidance
1. What is the POU4F3 gene test and why is it recommended?
The POU4F3 NGS test precisely identifies disease‑causing variants in the POU4F3 gene responsible for autosomal dominant progressive hearing loss (DFNA15). It is recommended when family history suggests DFNA15 deafness or when a patient presents with non‑syndromic sensorineural hearing loss of unknown cause, to confirm the diagnosis and guide management.
2. What sample is required and how is home collection arranged?
A simple blood sample, extracted DNA, or a single drop of blood on an FTA card is collected via our DHA‑licensed VIP Mobile Phlebotomy service within 24 hours. Our temperature‑controlled cold‑chain logistics ensure sample stability; a dedicated mobile nurse visits at a time you choose (8 AM – 11 PM).
3. How accurate is this test and what do results mean?
Our ISO‑certified NGS platform provides 99.9% analytical sensitivity, with clinical interpretation by board‑certified geneticists and ENT specialists. A positive result confirms a pathogenic variant; a negative result reduces the likelihood of DFNA15 but does not exclude other genetic or acquired hearing loss causes.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in full compliance with UAE federal laws: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All data is encrypted and processed within the UAE under the jurisdiction of the Dubai Health Authority (DHA).
Clinical & Logistical Metadata
| Test Name | POU4F3 Gene Deafness (Autosomal Dominant Type 15) Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Blood (whole blood, extracted DNA, or FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 48304-3 |
| DHA Facility License & Laboratory Address | License: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians